CHICAGO (Reuters) - Virtually all of the experts who wrote favorably about GlaxoSmithKline Plc's troubled diabetes drug Avandia had financial ties to drug makers, a finding that shows the need for reform of such relationships, U.S. researchers said on Thursday. A team at the Mayo Clinic in Rochester, Minnesota, pored through more than 200 scientific studies and commentaries that ...

Ligand Pharmaceuticals Inc. said Friday that partner GlaxoSmithKline gained European regulatory approval to sell the blood disorder drug Revolade. In December, a European advisory committee recommended approving the drug. It was discovered by Ligand, is already approved in the U.S. as Promacta. Ligand's licensing partner GlaxoSmithKline handled the European ...

LONDON (Reuters) - Several drug firms have agreed on a landmark deal to supply up to 200 million doses a year of cut-price pneumococcal vaccines to developing nations, according to the global immunization alliance that is overseeing the deal. Leading manufacturers of such vaccines include GlaxoSmithKline and Pfizer. The agreement is the first under a new scheme called an Advance Market ...

Nabi Pharmaceuticals said Monday it closed an option and license agreement for the smoking vaccine candidate NicVAx with GlaxoSmithKline. The deal is potentially worth more than $500 million, including a $40 million upfront payment to Nabi and future milestone and royalty payments. Nabi shareholders voted in favor of the deal ...